Grants and Contracts Details
Description
Project summary
Tauopathies including Alzheimer’s disease (AD) consist of age-associated neurodegenerative diseases for
which no disease-modifying treatments exist. Our group has uncovered a unique interaction between the
arginine metabolism and tauopathies. Arginine metabolism affects multiple biological processes that show
considerable influence upon tau biology. We hypothesize that L-arginine acts as a sensor for amino acid
abundance and that the depletion of arginine initiates autophagy to replenish amino acid levels. Arginase 1
(Arg1) remains one of several different enzymes capable of metabolizing the semi-essential amino acid L-
arginine. In fact numerous isoforms exist for Arg and nitric oxide synthases (NOS). We demonstrate in cells
and animal models of tauopathy the benefits of increasing Arg1 in reducing many aspects of the tau phenotype
(hallmarks comprised of tau effects). Several seminal findings show lysosomal and cytoplasmic arginine
sensors that modulate mechanistic target of rapamycin complex 1 (mTORC1). GPRC6a is a G-protein coupled
receptor that binds L-α amino acids including L-arginine and may serve as an extracellular arginine sensor for
mTORC1. Our preliminary data indicates increased activation of the arginine-sensing mTORC1 pathway in AD
brains and animal models of tauopathies. We show that arginine producing and metabolizing enzymes,
arginine sensors, and mTORC1 complexes increase in the hippocampus of AD patients compared to control
aged matched brains. We also find that tau increased total arginine levels in the brain by 35%, increased basal
levels of extracellular arginine and arginine release following neuronal stimulation in the brain. Furthermore,
novel allosteric antagonist to GPRC6a clears various forms of tau in cell lines, primary neurons, and mice.
Genetic reduction of GPRC6a also reduced tau expression and seemingly regulates several intracellular
arginine sensors. We posit that tauopathies (including AD) cause impaired arginine metabolism and uncoupling
of arginine-sensing mTORC1 signaling, which lead to hyper-mTORC1 activation creating a positive feed-
forward loop to augment the tau phenotype. We will test the hypothesis that decreased GPRC6a signaling from
allosteric antagonists or shRNA to GPRC6a modulate arginine-sensing mTORC1 signaling, induces autophagy
and increases tau clearance in vitro and in vivo. We will use tetracycline inducible tau cell lines with a photo-
switchable fluorescent tracer to measure tau metabolism, split tau-GFP constructs that measure tau
oligomerization, and primary neurons to determine the role of GPRC6a and tau fate. We will determine if
genetic knockdown and pharmacological inhibition of GPRC6a impacts tau biology in vitro and in vivo. Success
in this application would provide a new receptor target that may impact arginine-sensing mTORC1 signaling.
Furthermore, we aim to identify an entirely new class of drugs that targets GPCR6a to mitigate the tau
phenotype provide new strategies for tauopathies and AD.
Status | Finished |
---|---|
Effective start/end date | 7/8/18 → 3/31/24 |
Funding
- National Institute on Aging: $285,316.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.